Gut Microbiome Shifts Linked to Chronic Systolic Heart Failure Severity and Recovery
A recent multi-omic study published in Nature Cardiovascular Research links alterations in the gut microbiome, microbial metabolites, and changes in heart function to chronic systolic heart failure due to nonischemic cardiomyopathy. Conducted by researchers investigating biological relationships in heart disease progression, the study identifies specific bacterial populations, such as Bifidobacterium and short-chain fatty acid producers, that correlate with disease severity and functional improvement.
Operational Impact for Clinical and Research IT
- Multi-Omic Integration: Combines metagenomics, metabolomics, and gene set enrichment analysis (GSEA) to map microbial profiles against clinical outcomes.
- Longitudinal Cohort Data: Evaluates patients at baseline, six months, and an average of 27 months to track disease trajectories and functional shifts.
- Metabolic Biomarkers: Links circulating indole-3-propionic acid (IPA) and predicted microbial butyrate production to milder heart failure measures.
Multi-Omic Profiling of the Gut Microbiome in Chronic Systolic Heart Failure
Chronic systolic heart failure (HF) presents significant morbidity and mortality risks, with disease trajectories remaining poorly understood despite its rising prevalence. To investigate how the gut microbiome contributes to underlying biological pathways, researchers integrated microbiome and host multi-omic profiling. Stool samples underwent metagenomic sequencing to reveal gut microbiome composition, while differential abundance analysis identified microbial changes associated with HF. Metabolomics assessed microbiome-derived metabolites, and GSEA pinpointed functional groups linked to the condition.
The study population comprised 59 adults with chronic HF due to nonischemic cardiomyopathy (NICM), enrolled between July 2018 and March 2020, alongside 50 healthy participants from the integrated Personal Omics Profiling (iPOP) study. Researchers applied strict exclusion criteria, removing individuals with primary ischemic cardiomyopathy, complex congenital heart disease, treated diabetes, advanced kidney or liver disease, autoimmune disorders, active malignancies, recent abdominal surgery, or recent use of probiotics, antibiotics, radiation, or chemotherapy. NICM patients in the cohort exhibited markedly reduced left ventricular ejection fraction (LVEF), mild-to-moderate left ventricular dilatation, and impaired right ventricular function, though they were generally clinically well compensated.
Longitudinal Assessments and Clinical Outcomes Tracking
To capture shifts over time, the research team conducted longitudinal analyses on a subset of the cohort. A group of 26 HF patients came back for repeat clinical evaluation and multi-omic profiling after an average of six months, whereas 51 patients provided longer-term clinical follow-up data after an average of 27 months. Clinical outcomes were assessed based on heart transplantation, placement of a left ventricular assist device (LVAD), hospice care, or death.
Clinical improvement was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ-23), New York Heart Association (NYHA) functional classes, and LVEF. To qualify as improved during the six-month assessment, participants had to show a minimum five-point rise in their overall KCCQ summary score, a drop of at least one NYHA class, or a 5% or greater increase in LVEF. Machine learning models integrated laboratory, cytokine, microbiota, and microbial pathway data to successfully distinguish HF patients from healthy control participants.
Depletion of Anti-Inflammatory Microbes and Altered Metabolic Pathways
Results from the metagenomic and metabolomic analyses showed that the guts of HF patients experienced a depletion in alpha diversity and anti-inflammatory microbes. Specifically, Bifidobacterium and short-chain fatty acid (SCFA)-producing microbes were reduced compared to healthy controls. Furthermore, HF patients displayed lower levels of the Lachnospiraceae family and the genera Anaerobutyricum, Anaerostipes, Blautia, and Lachnospira. Conversely, the genera Prevotella and Sutterella, which have links to pro-inflammatory host responses, showed enrichment in the HF group.
Functional analysis indicated that pathways associated with SCFA, methane, and L-arginine production, along with formaldehyde detoxification, were downregulated in HF patients. At the same time, pathways involved in pro-inflammatory lipopolysaccharide (LPS) generation showed enrichment. Altered L-arginine and ornithine pathways were tied to varying microbiome-immune interactions. While these pathways influence gut barrier function, inflammation, and the production of nitric oxide and polyamines, the study did not establish that microbiome shifts directly altered their systemic production.
Bifidobacterium Abundance and Microbial Metabolite Correlations
Among the specific findings, Bifidobacterium—certain strains of which produced indole-3-propionic acid (IPA) in laboratory experiments—demonstrated a notable relationship with heart failure measures. Greater Bifidobacterium abundance mapped to milder disease severity and improved functional status. Similarly, higher circulating levels of IPA and predicted microbial butyrate production correlated with milder HF measures, providing concrete targets for future mechanistic research into microbiome-host interactions.